Suicide is a global public health problem with particular resonance for the US military.
OR = 2.88, p = 5.24E-10. These findings were not replicated in the European ancestry subsamples of the replication or suicide attempters samples. However, the association of the peak SNP remained significant in a meta-analysis of all studies and ancestral subgroups (OR = 2.18, 95%CI 1.70, 2.80). Polygenic risk score (PRS) analyses showed some association of SA with bipolar disorder. The association with SNPs encompassing MRAP2, a gene expressed in brain and adrenal cortex and involved in neural control of energy homeostasis, points to this locus as a plausible susceptibility gene for suicidality that should be further studied. Larger sample sizes will be needed to confirm and extend these findings.
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genetics, genomewide association, military, risk, suicide, suicide attempt 1 | INTRODUCTIONS uicide morbidity and mortality constitute a major global public health problem (Whiteford et al., 2013) . The age-adjusted death rate from suicide in the United States has climbed steadily for the past 15 years (through 2014, the most recent year for which data are publicly available) and suicide now ranks as the third leading cause of death among older adolescents and young adults ages 15-24 (www.cdc.gov/nchs/faststas/ death.htm). Suicide is of particular concern to the US military, where suicide attempts are among the leading causes of injury. Moreover, death by suicide recently surpassed combat casualty as the most frequent cause of death among active-duty Servicemembers (Armed Forces Health Surveillance Center, 2014). Though suicide rates in the US Army have historically been lower than in the general population, this trend has changed in recent years (Anglemyer, Miller, Buttrey, & Whitaker, 2016) leading to intensive suicide prevention efforts (Engel, 2013; Ursano, 2013) .
Numerous recent studies have focused on predictors of suicidality in the US military. These studies have tended to converge upon several risk factors shared with the civilian sector (e.g., demographics of young adults, particularly males; depression and other mental disorders, and history of childhood maltreatment; Afifi et al., 2016) and others unique to the military (e.g., deployment experiences) (LeardMann et al., 2013; Nock et al., 2014; Ramsawh et al., 2014; Ursano et al., 2015) . This attention to risk factors has extended to genetic and other biological factors (Oquendo et al., 2016; Sudol & Mann, 2017; Turecki, 2014) , with the goal of developing a bio-signature for suicide (Oquendo et al., 2014) .
Recent reports of a combined genetic-epigenetic risk marker for suicidality in SKA2 (Guintivano et al., 2014; Kaminsky et al., 2015) are of considerable interest, and await further replication in population-based samples, as do other multivariate approaches that incorporate genomic and clinical risk factors (Niculescu, Levey, Phalen, et al., 2015) . Although twin studies have documented genetic influences on suicide-related phenotypes (heritability ∼30-55%) (Tidemalm et al., 2011) , it is clear that suicidality is a multi-determined, genetically complex trait, as is the case for virtually all mental and behavioral disorders (Gelernter, 2015) .
Thus, a great many genes and genomic processes (e.g., epistasis and epigenetic variation) are likely to contribute to risk for suicidality, but none have been firmly established (Niculescu, Levey, Le-Niculescu, et al., 2015; Oquendo et al., 2014; Sokolowski, Wasserman, & Wasserman, 2014; Turecki, 2014; Yin et al., 2016) .
Several genomewide association studies (GWAS) of suicidality have been reported (Mirkovic et al., 2016) , mostly limited to analyses of suicide attempts among patients with mood disorders. In four large GWAS comparing mood disorder patients (bipolar and/or major depressive disorder) with and without a history of suicide attempts, no genomewide significant (GWS) loci were detected (Galfalvy et al., 2015; Perlis et al., 2010; Schosser et al., 2011; Willour et al., 2012) . A recent report applying polygenic risk score (PRS) analysis to depressed patients in the RADIANT study across suicidal ideation and suicide attempts found no genetic overlap between those two phenotypes, leading the authors to conclude that the tendency to think about suicide and the tendency to act on suicidal thoughts may be influenced by substantially non-overlapping genetic factors (Mullins et al., 2014) . There is only partial overlap in epidemiological risk factors for suicidal ideation and attempts (Nock et al., 2013) . Thus, genetic factors influencing these various facets of suicidality may also be different and should be examined separately.
In the present study, we utilized population-based nonclinical cohorts of US military personnel and one clinical sample from the same US military population to conduct GWAS of suicide attempts (SA). We also used genomewide genotype data to examine polygenic risk for SA in relation to Psychiatric Genomics Consortium (PGC) PRS for major depressive disorder Pre-/Post-Deployment Study (PPDS), and Soldier Health Outcomes Study A (SHOS-A). Detailed information about the design and conduct of STARRS is available in a separate report 
| Soldier health outcomes study A (SHOS-A)
The SHOS-A is a clinical case-control study of soldiers hospitalized following an acute suicide attempt. This study compared soldiers who attempted suicide (cases) with non-hospitalized Army controls without lifetime suicide attempts matched on a variety of measures including demographics, general psychiatric distress, and psychiatric disorder.
The 95 cases and 168 controls for which DNA samples were available are included.
| Measures
The SAQ surveyed socio-demographic characteristics including lifetime and past-30-day mental disorders, and an array of potential risk and resilience factors. SHOS-A included additional information about the circumstances of the index suicide attempt.
| Suicidality assessment
Suicidal behaviors were assessed using a version of the Columbia Suicidal Severity Rating Scale (C-SSRS) (Posner et al., 2011) assessing lifetime occurrence of suicide ideation ("Did you ever in your life have thoughts of killing yourself" or "Did you ever wish you were dead or would go to sleep and never wake up?") and, among respondents who reported lifetime suicide ideation, suicide plans ("Did you ever have any intention to act [on these thoughts/on that wish]?" and, if so, "Did you ever think about how you might kill yourself [e.g., taking pills, shooting yourself] or work out a plan of how to kill yourself?") and suicide attempts ("Did you ever make a suicide attempt [i.e., purposefully hurt yourself with at least some intention to die]?"). For the primary analysis, controls are those individuals with no lifetime history of SA (who may or may not have a lifetime history of suicidal ideation).
| Genetic data collection and procedures
NSS1 and PPDS samples were genotyped using the Illumina OmniExpress + Exome array with additional custom content. NSS2
and SHOS-A samples were genotyped on the Ilumina PsychChip.
Quality control (QC) of genotype data used standard protocols as described elsewhere (Stein et al., 2016) . Relatedness testing was carried out with PLINK v1.90 (Chang et al., 2015) and, for pairs of subjects with π of >0.2, one member of each relative pair was removed at random. We performed the following quality control procedure to obtain the genotype data for population assignment (see Supplemental Materials) and principal components analysis (PCA). We retained GWAS were conducted in PLINK v1.90 (Chang et al., 2015) using the logistic regression model, the allelic dosage files generated from 
| Polygenic risk scores (PRS)
PRS analyses for the SA phenotype were computed using PLINK in the EUR subsamples only because of the unavailability of reference GWAS data for the other populations with no LD trimming (Chang et al., 2015) . 
| Suicide attempts (SA)
Figure 1a-c shows the results of the SA GWAS meta-analyses of NSS(1,2) in the three ancestral groups; no inflation of test statistics was observed in the GWAS NSS meta-analytic results (λ = 0.98-1.00).
There was one genome-wide significant (GWS) SNP in the AFR group, rs144662392, p = 7.65 × 10 −9 , but it was a lone SNP and considered NSS, new soldier study; PPDS, pre-and post-deployment study; SHOS-A, soldier health outcomes study; CHR, chromosome; BP, genomic location in kilobases; SNP, single-nucleotide polymorphism; A1, effect allele; A2, non-effect allele; OR, odds ratio; FRQ, frequency of effect allele in the sample. We used a threshold of 0.8 for INFO score to filter out any poorly imputed SNPs. All SNPs in this table are imputed. The p-value for the smallest genotyped SNP in that region for the EUR NSS1/2 meta-analysis (rs7741955 A, 84829622) was 2.278e-07 OR = 2.1187. Logistic models adjusted for 10 ancestrally specific principal components.
a Remained genome-wide significant after controlling for lifetime history of major depressive episode(s).
likely to be a spurious finding. One gene region, all within a span of ∼200 K bp located on Chr 6, had several loci with meta-analytic GWS results for SA in the EUR group. Many of the SNPs are in high LD (r 2 ≥ 0.8). The regional plot in Figure 2a shows that the signal is near the MRAP2 and CEP162 (also known as KIAA1009 or QN1) genes on
Chr 6. Figure 2b shows that the signal remains with multiple genomewide significant results even when adjusted for lifetime major depression. (Table 2 ). This suggests that the region is not just operating through major depression to influence SA.
SNP lookups of top results from previous GWAS suicidality studies (Galfalvy et al., 2015; Perlis et al., 2010; Schosser et al., 2011; Willour et al., 2012) showed no statistically significant replication in any of our studies (Supplementary Table S2 The fixed-effects meta-analysis shows an overall statistically significant effect, which appears to be driven by effects in the European subjects. Table S3] ) at multiple p-value cutoff thresholds (Table 3) .
| Polygenic risk scores (PRS)

| Gene-based and pathway analyses
We performed gene and pathway enrichment analyses on the NSS1, genome-wide association studies provide the opportunity to discover biological systems that had not previously been implicated. Prior genetic association studies of suicidality have relied on clinical or other targeted samples, primarily patients with mood disorders (Galfalvy et al., 2015; Perlis et al., 2010; Schosser et al., 2011; Willour et al., 2012) , or patients taking antidepressant medication (Menke et al., 2012; Perroud et al., 2012) . Since suicide attempts occur at substantial rates outside of clinically identified samples, examining non-clinical, population-based samples is important to fully understand genetic and other risk factors for SA, which may differ depending on sample characteristics (Mirkovic et al., 2016) . We focused on soldiers in the US Army, where better understanding and prevention of suicidality has been a major concern (Engel, 2013; LeardMann et al., 2013; Nock et al., 2014; Ursano et al., 2015) .
We identified one GWS region in the EUR NSS(1,2) meta-analysis that includes the genes CEP162 (involved in ciliary function and mitotic spindle assembly (Leon, Omri, Gely, Klein, & Crisanti, 2006; Wang et al., 2013) and MRAP2 (melanocortin 2 receptor accessory protein 2), a paralogue of MRAP. A role for CEP162, involved in required to promote assembly of the transition zone in primary cilia (Wang et al., 2013) , cannot be discounted, though it is not an obvious candidate.
The product of MRAP2, M2CR accessory protein, supports M2CR cell surface expression necessary for the production of a functional ACTHresponsive melanocortin receptor (Chan et al., 2009; Novoselova, Jackson, Campbell, Clark, & Chan, 2013) . MRAP2 is expressed in brain NSS, new soldier study; PPDS, pre-/post-deployment study; SHOS-A, soldier health outcomes study A; PGC, psychiatric genomics consortium; MDD, major depressive disorder. PRS cutoff, p-value threshold for GWAS SNPs to enter the PGS. p-value, PRS p-value in logistic model adjusted for PC1-PC10. R and adrenal tissue, where it is involved with neural control of energy homeostasis, possibly through Mrap2 interaction with the melanocortin-4-receptor (Mc4r) affecting receptor signaling (Dores, Liang, Davis, Thomas, & Petko, 2016; Jackson, Ramachandrappa, Clark, & Chan, 2015) . Loss of MRAP2 function has been linked to obesity (Asai et al., 2013) but, to the best of our knowledge, has not been previously linked to suicidality or depressive illness. Given the presumed importance of HPA-axis function and glucocorticoid regulation in depressive illness and suicidality, these observations in concert with the findings that rare MRAP mutations may cause primary adrenal insufficiency (Guran et al., 2016) suggest that sequencing of this region may yield new insights into the genetic bases for suicidality.
Recent work with polygenic risk scores (PRSs) for suicide attempts in other cohorts has pointed to a role for neurodevelopmental genes (Sokolowski, Wasserman, & Wasserman, 2016) , though MRAP2 or CEP162, per se, were not specifically mentioned in that report. We observed an association between a PRS derived from the PGC-bipolar disorder analysis and SA in PPDS and SHOS-A. Although these associations were quite modest and require replication, they are consistent with the hypothesis of shared genetic risk between SA and bipolar disorder. A further caveat in interpreting these PRS associations is that we did not consider bipolar disorder in our case-control definitions. It is therefore conceivable that the PRS associations seen with bipolar disorder and SA may reflect an excess of bipolar disorder in cases. Similarly, although we did adjust for major depressive episode in sensitivity analyses of the EUR sample and found no appreciable decrement in the strength of association with MRAP2/CEP162, it is conceivable that other disorders (e.g., PTSD) associated with SA might be confounders of this association. Additional research with larger samples will be needed to exclude this possibility.
Our results should also be interpreted in light of several other limitations. The small sample size and likely heterogeneity may explain the failure to see the GWS results for MRAP2/CEP162 extend into the PPDS or SHOS-A samples, both of which contained far fewer numbers of SA cases than the NSS discovery sample. The NSS sample, it should be remembered, was based on reporting of SA prior to entering the military. Future studies will need to address this heterogeneity either by stratifying phenotypes differently (e.g., early-onset SA), incorporating informative covariates that may improve power (e.g., childhood maltreatment history or other psychosocial risk factors for SA) (Kaminsky et al., 2015) , or attaining much larger sample sizes. Lastly, we recognize that the findings from this study may not generalize beyond military personnel who have self-selected for service and may also have unique experiences as part of military service. Additionally, our sample is mostly male. It may be that the genetic factors influencing suicidality vary by sex, but we lacked the power to test this hypothesis.
In summary, despite this being the largest population-based GWAS study of SA to date, and the first in military population-based cohorts, the number of cases was small. The meta-analytic association of SNPs encompassing MRAP2, a gene expressed in brain and adrenal cortex and involved in neural control of energy homeostasis, points to this locus as a credible susceptibility gene for suicidality whose function should be further studied in larger human subject samples and in animal models of suicidal behaviors (Gould et al., 2017) .
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